Monoamine transporters: vulnerable and vital doorkeepers.

Transporters of dopamine, serotonin, and norepinephrine have been empirically used as medication targets for several mental illnesses in the last decades. These protein-targeted medications are effective only for subpopulations of patients with transporter-related brain disorders. Since the cDNA clonings in early 1990s, molecular studies of these transporters have revealed a wealth of information about the transporters' structure-activity relationship (SAR), neuropharmacology, cell biology, biochemistry, pharmacogenetics, and the diseases related to the human genes encoding these transporters among related regulators. Such new information creates a unique opportunity to develop transporter-specific medications based on SAR, mRNA, DNA, and perhaps transporter trafficking regulation for a number of highly relevant diseases including substance abuse, depression, schizophrenia, and Parkinson's disease.

[1]  H. Gu,et al.  Cocaine does not produce reward in absence of dopamine transporter inhibition , 2009, Neuroreport.

[2]  Guangyun Sun,et al.  Association of tagging single nucleotide polymorphisms on 8 candidate genes in dopaminergic pathway with schizophrenia in Croatian population. , 2009, Croatian medical journal.

[3]  J. Javitch,et al.  Symmetrical dimer of the human dopamine transporter revealed by cross-linking Cys-306 at the extracellular end of the sixth transmembrane segment , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[4]  A. Sorkin,et al.  Lysine 63-linked Polyubiquitination of the Dopamine Transporter Requires WW3 and WW4 Domains of Nedd4-2 and UBE2D Ubiquitin-conjugating Enzymes* , 2010, The Journal of Biological Chemistry.

[5]  T. Kinnunen,et al.  Smoking Cessation in Individuals with Depression , 1999 .

[6]  Joseph Piven,et al.  Cerebral cortical gray matter overgrowth and functional variation of the serotonin transporter gene in autism. , 2007, Archives of general psychiatry.

[7]  M. Burmeister,et al.  Meta‐analysis of the association between a serotonin transporter promoter polymorphism (5‐HTTLPR) and anxiety‐related personality traits , 2004, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[8]  B. Franke,et al.  American Journal of Medical Genetics Part B: Neuropsychiatric Genetics Early View (articles Online in Advance of Print) Response to Methylphenidate in Adults with Adhd Is Associated with a Polymorphism in Slc6a3 (dat1) , 2022 .

[9]  N. Volkow,et al.  Effects of route of administration on cocaine induced dopamine transporter blockade in the human brain. , 2000, Life sciences.

[10]  Beate Ritz,et al.  Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women. , 2006, Human molecular genetics.

[11]  R. Rodriguiz,et al.  Vmat2 Heterozygous Mutant Mice Display a Depressive-Like Phenotype , 2007, The Journal of Neuroscience.

[12]  R. Spealman.  Noradrenergic involvement in the discriminative stimulus effects of cocaine in squirrel monkeys. , 1995, The Journal of pharmacology and experimental therapeutics.

[13]  R. Vaughan.  Phosphorylation and Regulation of Psychostimulant-Sensitive Neurotransmitter Transporters , 2004, Journal of Pharmacology and Experimental Therapeutics.

[14]  A. Levey,et al.  Increased MPTP Neurotoxicity in Vesicular Monoamine Transporter 2 Heterozygote Knockout Mice , 1998, Journal of neurochemistry.

[15]  D. Murphy,et al.  Locomotory patterns, spatiotemporal organization of exploration and spatial memory in serotonin transporter knockout mice , 2007, Brain Research.

[16]  D. Murphy,et al.  Tramadol and another atypical opioid meperidine have exaggerated serotonin syndrome behavioural effects, but decreased analgesic effects, in genetically deficient serotonin transporter (SERT) mice. , 2009, The international journal of neuropsychopharmacology.

[17]  S. Hodge,et al.  Panic disorder is associated with the serotonin transporter gene (SLC6A4) but not the promoter region (5-HTTLPR) , 2010, Molecular Psychiatry.

[18]  H. Niki,et al.  Food‐Reinforced Operant Behavior in Dopamine Transporter Knockout Mice: Enhanced Resistance to Extinction , 2004, Annals of the New York Academy of Sciences.

[19]  Sohita Dhillon,et al.  Spotlight on Bupropion in Major Depressive Disorder , 2008, CNS drugs.

[20]  A. Newman,et al.  Dopamine transport inhibitors based on GBR12909 and benztropine as potential medications to treat cocaine addiction. , 2008, Biochemical pharmacology.

[21]  D. Murphy,et al.  Evaluation of Antidepressant-related Behavioral Responses in Mice Lacking the Serotonin Transporter , 2002, Neuropsychopharmacology.

[22]  J. Amsterdam.  Selective serotonin reuptake inhibitor efficacy in severe and melancholic depression , 1998, Journal of psychopharmacology.

[23]  D. Sulzer,et al.  Mechanisms of neurotransmitter release by amphetamines: A review , 2005, Progress in Neurobiology.

[24]  I. Anderson,et al.  Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. , 2000, Journal of affective disorders.

[25]  M. R. Sargolzaee,et al.  Association analysis of the dopamine transporter (DAT1)‐67A/T polymorphism in bipolar disorder , 2005, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[26]  G. Uhl,et al.  SLC18A2 promoter haplotypes and identification of a novel protective factor against alcoholism. , 2005, Human molecular genetics.

[27]  L. Christiansen,et al.  Candidate Gene Polymorphisms in the Serotonergic Pathway: Influence on Depression Symptomatology in an Elderly Population , 2007, Biological Psychiatry.

[28]  H. Sitte,et al.  Calmodulin Kinase II Interacts with the Dopamine Transporter C Terminus to Regulate Amphetamine-Induced Reverse Transport , 2006, Neuron.

[29]  Martin H. Teicher,et al.  A polymorphism in the norepinephrine transporter gene alters promoter activity and is associated with attention-deficit hyperactivity disorder , 2006, Proceedings of the National Academy of Sciences.

[30]  I. Sora,et al.  Methamphetamine-induced locomotor activity and sensitization in dopamine transporter and vesicular monoamine transporter 2 double mutant mice , 2007, Psychopharmacology.

[31]  M. Caron,et al.  Effect of Antidepressant Drugs in Mice Lacking the Norepinephrine Transporter , 2006, Neuropsychopharmacology.

[32]  F. Lee,et al.  Disruption of the dopamine transporter–dopamine D2 receptor interaction in schizophrenia , 2009, Synapse.

[33]  G. Davey,et al.  Worry and its psychological disorders: theory, assessment and treatment , 2006 .

[34]  N. Wray,et al.  Accurate, Large-Scale Genotyping of 5HTTLPR and Flanking Single Nucleotide Polymorphisms in an Association Study of Depression, Anxiety, and Personality Measures , 2009, Biological Psychiatry.

[35]  S. Clarke,et al.  Anorexia nervosa (restrictive subtype) is associated with a polymorphism in the novel norepinephrine transporter gene promoter polymorphic region , 2002, Molecular Psychiatry.

[36]  M. Quick.  Regulating the Conducting States of a Mammalian Serotonin Transporter , 2003, Neuron.

[37]  B. Rocha,et al.  Intravenous cocaine induced‐activity and behavioural sensitization in norepinephrine‐, but not dopamine‐transporter knockout mice , 2002, The European journal of neuroscience.

[38]  M. Thase,et al.  Pharmacotherapy of mood disorders. , 2008, Annual review of clinical psychology.

[39]  A. Ravna,et al.  A homology model of SERT based on the LeuT(Aa) template. , 2006, Bioorganic & medicinal chemistry letters.

[40]  T. Sotnikova,et al.  Sustained elevation of extracellular dopamine causes motor dysfunction and selective degeneration of striatal GABAergic neurons , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[41]  P. Greengard,et al.  Cocaine Increases Dopamine Release by Mobilization of a Synapsin-Dependent Reserve Pool , 2006, The Journal of Neuroscience.

[42]  H. Sitte,et al.  Relationship between Conformational Changes in the Dopamine Transporter and Cocaine-Like Subjective Effects of Uptake Inhibitors , 2008, Molecular Pharmacology.

[43]  L. Çelik,et al.  Binding of serotonin to the human serotonin transporter. Molecular modeling and experimental validation. , 2008, Journal of the American Chemical Society.

[44]  G. Tsai,et al.  Association between serotonin transporter gene promoter polymorphism and suicide: results of a meta-analysis , 2004, Biological Psychiatry.

[45]  R. Béliveau,et al.  The in situ size of the dopamine transporter is a tetramer as estimated by radiation inactivation. , 1994, Biochimica et biophysica acta.

[46]  Makito Hirano,et al.  Increased vulnerability to l-DOPA toxicity in dopaminergic neurons from VMAT2 heterozygote knockout mice , 2007, Journal of Molecular Neuroscience.

[47]  A. Cools,et al.  Serotonin transporter deficiency in rats contributes to impaired object memory , 2009, Genes, brain, and behavior.

[48]  M. Munafo,et al.  Does measurement instrument moderate the association between the serotonin transporter gene and anxiety-related personality traits? A meta-analysis , 2005, Molecular Psychiatry.

[49]  I. Anderson,et al.  Pharmacological Treatments for Worry: Focus on Generalised Anxiety Disorder , 2008 .

[50]  H. Groenewegen.  The Basal Ganglia and Motor Control , 2003, Neural plasticity.

[51]  D. Balfour,et al.  The Effects of Nicotine on Neural Pathways Implicated in Depression A Factor in Nicotine Addiction? , 2000, Pharmacology Biochemistry and Behavior.

[52]  J. Canales,et al.  The Dopamine Uptake Inhibitor 3α-[bis(4′-fluorophenyl)metoxy]-tropane Reduces Cocaine-Induced Early-Gene Expression, Locomotor Activity, and Conditioned Reward , 2009, Neuropsychopharmacology.

[53]  D. Clair,et al.  Pharacogenetic effects of dopamine transporter gene polymorphisms on response to chlorpromazine and clozapine and on extrapyramidal syndrome in schizophrenia , 2010, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[54]  P. Riederer,et al.  Allelic variation of serotonin transporter expression is associated with depression in Parkinson's disease , 2001, Molecular Psychiatry.

[55]  Nikos Makris,et al.  Effect of dopamine transporter gene (SLC6A3) variation on dorsal anterior cingulate function in attention‐deficit/hyperactivity disorder , 2010, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[56]  Xiao-hong Ma,et al.  Monoamine transporter gene polymorphisms affect susceptibility to depression and predict antidepressant response , 2009, Psychopharmacology.

[57]  P. Cowen,et al.  Decreased sensitivity of 5-HT1D receptors in melancholic depression , 2001, British Journal of Psychiatry.

[58]  Jian Feng,et al.  Parkin Increases Dopamine Uptake by Enhancing the Cell Surface Expression of Dopamine Transporter* , 2004, Journal of Biological Chemistry.

[59]  J. Kelsoe,et al.  Promoter and intronic variants affect the transcriptional regulation of the human dopamine transporter gene. , 2003, Genomics.

[60]  R. Lewis,et al.  Emerging structure-function relationships defining monoamine NSS transporter substrate and ligand affinity. , 2010, Biochemical pharmacology.

[61]  M. Leitges,et al.  Protein Kinase Cβ Is a Critical Regulator of Dopamine Transporter Trafficking and Regulates the Behavioral Response to Amphetamine in Mice , 2009, Journal of Pharmacology and Experimental Therapeutics.

[62]  Jürgen Gallinat,et al.  Variations in the Vesicular Monoamine Transporter 1 Gene (VMAT1/SLC18A1) are Associated with Bipolar I Disorder , 2006, Neuropsychopharmacology.

[63]  Rachel A. Millstein,et al.  Insertion mutation at the C-terminus of the serotonin transporter disrupts brain serotonin function and emotion-related behaviors in mice , 2006, Neuroscience.

[64]  C. Carlson,et al.  5' and 3' region variability in the dopamine transporter gene (SLC6A3), pesticide exposure and Parkinson's disease risk: a hypothesis-generating study. , 2006, Human molecular genetics.

[65]  C. Tung,et al.  Alpha adrenergic modulation on effects of norepinephrine transporter inhibitor reboxetine in five-choice serial reaction time task , 2009, Journal of Biomedical Science.

[66]  P Riederer,et al.  Allelic Variation of Human Serotonin Transporter Gene Expression , 1996, Journal of neurochemistry.

[67]  Bruno Giros,et al.  Parallel Loss of Hippocampal LTD and Cognitive Flexibility in a Genetic Model of Hyperdopaminergia , 2007, Neuropsychopharmacology.

[68]  A. Cools,et al.  Adaptations in pre- and postsynaptic 5-HT1A receptor function and cocaine supersensitivity in serotonin transporter knockout rats , 2008, Psychopharmacology.

[69]  S. Ikemoto,et al.  The role of nucleus accumbens dopamine in motivated behavior: a unifying interpretation with special reference to reward-seeking , 1999, Brain Research Reviews.

[70]  Hans-Jürgen Möller,et al.  World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care , 2007, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[71]  Carrie C Buchanan,et al.  cGMP-dependent protein kinase Iα associates with the antidepressant-sensitive serotonin transporter and dictates rapid modulation of serotonin uptake , 2009, Molecular Brain.

[72]  A. Sorkin,et al.  Negative Regulation of Dopamine Transporter Endocytosis by Membrane-Proximal N-Terminal Residues , 2009, The Journal of Neuroscience.

[73]  M. Youdim,et al.  Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation. , 2004, Neurotoxicology.

[74]  E H Cook,et al.  Cocaine, ethanol, and genotype effects on human midbrain serotonin transporter binding sites and mRNA levels. , 1998, The American journal of psychiatry.

[75]  M. Gill,et al.  Functional analysis of intron 8 and 3′ UTR variable number of tandem repeats of SLC6A3: differential activity of intron 8 variants , 2010, The Pharmacogenomics Journal.

[76]  C. Otte,et al.  Association of a serotonin transporter polymorphism (5-HTTLPR) with depression, perceived stress, and norepinephrine in patients with coronary disease: the Heart and Soul Study. , 2007, The American journal of psychiatry.

[77]  S. Runyon,et al.  Dopamine transporter ligands: recent developments and therapeutic potential. , 2006, Current topics in medicinal chemistry.

[78]  A. Galzin,et al.  Studies on the serotonin transporter in platelets , 1988, Experientia.

[79]  J. Homberg,et al.  Acute and constitutive increases in central serotonin levels reduce social play behaviour in peri-adolescent rats , 2007, Psychopharmacology.

[80]  Jacqueline N. Crawley,et al.  Reduced aggression in mice lacking the serotonin transporter , 2002, Psychopharmacology.

[81]  A. Sidhu,et al.  Attenuation of the norepinephrine transporter activity and trafficking via interactions with α‐synuclein , 2006, The European journal of neuroscience.

[82]  J. C. Lodder,et al.  NMDA receptors trigger neurosecretion of 5‐HT within dorsal raphé nucleus of the rat in the absence of action potential firing , 2006, The Journal of physiology.

[83]  A. Hariri,et al.  Genetic variation in components of dopamine neurotransmission impacts ventral striatal reactivity associated with impulsivity , 2009, Molecular Psychiatry.

[84]  Randy D. Blakely,et al.  Expression cloning of a cocaine-and antidepressant-sensitive human noradrenaline transporter , 1991, Nature.

[85]  G. Hanson,et al.  Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity. , 2002, The Journal of pharmacology and experimental therapeutics.

[86]  R. Blakely,et al.  Serotonin-, Protein Kinase C-, and Hic-5-associated Redistribution of the Platelet Serotonin Transporter* , 2006, Journal of Biological Chemistry.

[87]  Frank Baas,et al.  Striatal Dopamine Transporter Availability Associated with Polymorphisms in the Dopamine Transporter Gene SLC6A3 , 2008, Journal of Nuclear Medicine.

[88]  S. Hansson,et al.  Ontogeny of vesicular monoamine transporter mRNAs VMAT1 and VMAT2. I. The developing rat central nervous system. , 1998, Brain research. Developmental brain research.

[89]  B. Hoffman,et al.  Expression cloning of a reserpine-sensitive vesicular monoamine transporter. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[90]  J. Ananth.  Clomipramine: An Antiobsessive Drug , 1986, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[91]  N. Buckley,et al.  Fatal toxicity of serotoninergic and other antidepressant drugs: analysis of United Kingdom mortality data , 2002, BMJ : British Medical Journal.

[92]  R. Ebstein,et al.  Associations between polymorphisms in dopamine neurotransmitter pathway genes and pain response in healthy humans , 2009, Pain.

[93]  D. Stein,et al.  The efficacy of the selective serotonin reuptake inhibitors for social anxiety disorder (social phobia): a meta‐analysis of randomized controlled trials , 2000, International clinical psychopharmacology.

[94]  L. Fañanás,et al.  Genetic polymorphisms in the dopamine-2 receptor (DRD2), dopamine-3 receptor (DRD3), and dopamine transporter (SLC6A3) genes in schizophrenia: Data from an association study , 2010, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[95]  A. Levey,et al.  Functional Interaction between Monoamine Plasma Membrane Transporters and the Synaptic PDZ Domain–Containing Protein PICK1 , 2001, Neuron.

[96]  G. Chrousos.  Stress and disorders of the stress system , 2009, Nature Reviews Endocrinology.

[97]  B. Guptaroy,et al.  Dopamine and Amphetamine Rapidly Increase Dopamine Transporter Trafficking to the Surface: Live-Cell Imaging Using Total Internal Reflection Fluorescence Microscopy , 2009, The Journal of Neuroscience.

[98]  E. Rüther,et al.  Pharmacological validation of a chronic social stress model of depression in rats: effects of reboxetine, haloperidol and diazepam , 2008, Behavioural pharmacology.

[99]  C. Berridge,et al.  The locus coeruleus–noradrenergic system: modulation of behavioral state and state-dependent cognitive processes , 2003, Brain Research Reviews.

[100]  U. John,et al.  Serotonin transporter gene (SLC6A4) promoter polymorphisms and the susceptibility to posttraumatic stress disorder in the general population. , 2009, The American journal of psychiatry.

[101]  H. Sitte,et al.  Sodium-dependent neurotransmitter transporters: oligomerization as a determinant of transporter function and trafficking. , 2004, Molecular interventions.

[102]  P. M. Chan,et al.  Mice with Very Low Expression of the Vesicular Monoamine Transporter 2 Gene Survive into Adulthood: Potential Mouse Model for Parkinsonism , 2001, Molecular and Cellular Biology.

[103]  A. Palmer,et al.  Further evidence of association between amphetamine response and SLC6A2 gene variants , 2009, Psychopharmacology.

[104]  P. Mecocci,et al.  Psychotic symptoms in Alzheimer's disease and 5-HTTLPR polymorphism of the serotonin transporter gene: evidence for an association. , 2009, Journal of Alzheimer's disease : JAD.

[105]  D. Murphy,et al.  The developing use of heterozygous mutant mouse models in brain monoamine transporter research. , 2007, Trends in pharmacological sciences.

[106]  J. Javitch,et al.  The Human Dopamine Transporter Forms a Tetramer in the Plasma Membrane , 2003, Journal of Biological Chemistry.

[107]  C. Kratochvil,et al.  Update on atomoxetine in the treatment of attention-deficit/hyperactivity disorder. , 2009, Expert opinion on pharmacotherapy.

[108]  A. A. Wijers,et al.  Variants of the SLC6A3 (DAT1) polymorphism affect performance monitoring-related cortical evoked potentials that are associated with ADHD , 2010, Biological Psychology.

[109]  Jeffry D Madura,et al.  Dopamine transporter comparative molecular modeling and binding site prediction using the LeuTAa leucine transporter as a template , 2008, Proteins.

[110]  G. Tocchini-Valentini,et al.  GPR37 associates with the dopamine transporter to modulate dopamine uptake and behavioral responses to dopaminergic drugs , 2007, Proceedings of the National Academy of Sciences.

[111]  N. Zahniser,et al.  Chronic and acute regulation of Na+/Cl- -dependent neurotransmitter transporters: drugs, substrates, presynaptic receptors, and signaling systems. , 2001, Pharmacology & therapeutics.

[112]  E. Khusnutdinova,et al.  Association of several polymorphic loci of serotoninergic genes with unipolar depression , 2009, Russian Journal of Genetics.

[113]  Lian Zhang,et al.  Loss of striatal vesicular monoamine transporter protein (VMAT2) in human cocaine users. , 2003, The American journal of psychiatry.

[114]  B. Rocha,et al.  Genetic deletion of the norepinephrine transporter decreases vulnerability to seizures , 2005, Neuroscience Letters.

[115]  S. Rauch,et al.  Association of SLC6A4 variants with obsessive-compulsive disorder in a large multi-center US family study , 2009, Molecular Psychiatry.

[116]  J. Javitch,et al.  Cocaine increases dopamine uptake and cell surface expression of dopamine transporters. , 2002, Biochemical and biophysical research communications.

[117]  L. Davis,et al.  Serotonin dysfunction disorders: a behavioral neurochemistry perspective. , 1996, The Journal of clinical psychiatry.

[118]  A. Addington,et al.  Molecular genetic studies of ADHD: 1991 to 2004 , 2006, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[119]  D. Murphy,et al.  Animal models of depression in dopamine, serotonin, and norepinephrine transporter knockout mice: prominent effects of dopamine transporter deletions , 2008, Behavioural pharmacology.

[120]  P. Andersen,et al.  The predictive effect of episodes on the risk of recurrence in depressive and bipolar disorders – a life‐long perspective , 2004, Acta psychiatrica Scandinavica.

[121]  Dong-Hwan Kim,et al.  Syntaxin 1A and Receptor for Activated C Kinase Interact with the N-Terminal Region of Human Dopamine Transporter , 2004, Neurochemical Research.

[122]  S. Amara,et al.  Regulated Trafficking of the Human Dopamine Transporter , 1999, The Journal of Biological Chemistry.

[123]  S. Gilman,et al.  Decreased striatal monoaminergic terminals in severe chronic alcoholism demonstrated with (+)[11C]Dihydrotetrabenazine and positron emission tomography , 1998, Annals of neurology.

[124]  M. Jaber,et al.  Motor behaviour deficits and their histopathological and functional correlates in the nigrostriatal system of dopamine transporter knockout mice , 2003, Neuroscience.

[125]  J. Javitch,et al.  Currents in Response to Rapid Concentration Jumps of Amphetamine Uncover Novel Aspects of Human Dopamine Transporter Function , 2008, The Journal of Neuroscience.

[126]  M. Caron,et al.  Oligomerization and Trafficking of the Human Dopamine Transporter , 2003, The Journal of Biological Chemistry.

[127]  J. Haycock,et al.  Differential trafficking of the vesicular monoamine transporter-2 by methamphetamine and cocaine. , 2002, European journal of pharmacology.

[128]  M. Fava,et al.  A preliminary open study of the tolerability and effectiveness of nefazodone in major depressive disorder: Comparing patients who recently discontinued an ssri with those on no recent antidepressant treatment , 2004, Depression and anxiety.

[129]  K. Ressler,et al.  Role of norepinephrine in the pathophysiology and treatment of mood disorders , 1999, Biological Psychiatry.

[130]  S. Galea,et al.  Modification of the association between serotonin transporter genotype and risk of posttraumatic stress disorder in adults by county-level social environment. , 2009, American journal of epidemiology.

[131]  M. Brownstein,et al.  Cloning of a serotonin transporter affected by antidepressants. , 1991, Science.

[132]  Lucy R Forrest,et al.  Fluoxetine (Prozac) Binding to Serotonin Transporter Is Modulated by Chloride and Conformational Changes , 2009, The Journal of Neuroscience.

[133]  J. Javitch,et al.  N-Terminal Phosphorylation of the Dopamine Transporter Is Required for Amphetamine-Induced Efflux , 2004, PLoS biology.

[134]  S. Higuchi,et al.  Serotonin transporter regulatory region polymorphism is associated with anorexia nervosa , 2004, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[135]  Sheila M. Thomas,et al.  The Multiple LIM Domain-Containing Adaptor Protein Hic-5 Synaptically Colocalizes and Interacts with the Dopamine Transporter , 2002, The Journal of Neuroscience.

[136]  Sanbing Shen,et al.  Increased Expression of the 5-HT Transporter Confers a Low- Anxiety Phenotype Linked to Decreased 5-HT Transmission , 2006, The Journal of Neuroscience.

[137]  J. Kelly,et al.  Reboxetine attenuates forced swim test-induced behavioural and neurochemical alterations in the rat , 1999, European Neuropsychopharmacology.

[138]  B. Madras,et al.  Polymorphisms in the 3′-untranslated region of human and monkey dopamine transporter genes affect reporter gene expression , 2002, Molecular Psychiatry.

[139]  W. Maier,et al.  Association of DNA Polymorphisms in the Synaptic Vesicular Amine Transporter Gene (SLC18A2) with Alcohol and Nicotine Dependence , 2005, Neuropsychopharmacology.

[140]  Gary W. Miller,et al.  Reduced Vesicular Storage of Dopamine Causes Progressive Nigrostriatal Neurodegeneration , 2007, The Journal of Neuroscience.

[141]  A. Schatzberg.  Pharmacological principles of antidepressant efficacy , 2002, Human psychopharmacology.

[142]  R. Hen,et al.  Hyperactivity and impaired response habituation in hyperdopaminergic mice. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[143]  A. Green.  Neuropharmacology of 5-hydroxytryptamine. , 2006, British journal of pharmacology.

[144]  Randy D Blakely,et al.  Serotonin and Cocaine-sensitive Inactivation of Human Serotonin Transporters by Methanethiosulfonates Targeted to Transmembrane Domain I* , 2003, Journal of Biological Chemistry.

[145]  F. Lee,et al.  Parkin Disrupts the α-Synuclein/Dopamine Transporter Interaction: Consequences Toward Dopamine-induced Toxicity , 2007, Journal of Molecular Neuroscience.

[146]  M. Bortolomasi,et al.  Serotonin transporter gene polymorphisms and treatment-resistant depression , 2010, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[147]  Rachel A. Millstein,et al.  Impaired Stress-Coping and Fear Extinction and Abnormal Corticolimbic Morphology in Serotonin Transporter Knock-Out Mice , 2007, The Journal of Neuroscience.

[148]  Heather A. Mitchell,et al.  The Effects of Chronic Norepinephrine Transporter Inactivation on Seizure Susceptibility in Mice , 2006, Neuropsychopharmacology.

[149]  A. Sorkin,et al.  Regulation of receptors and transporters by ubiquitination: new insights into surprisingly similar mechanisms. , 2007, Molecular interventions.

[150]  J. Seamans,et al.  The principal features and mechanisms of dopamine modulation in the prefrontal cortex , 2004, Progress in Neurobiology.

[151]  S. Amara,et al.  Cloning and expression of a cocaine-sensitive rat dopamine transporter. , 1991, Science.

[152]  D. Murphy,et al.  Receptor mediation of exaggerated responses to serotonin-enhancing drugs in serotonin transporter (SERT)-deficient mice , 2007, Neuropharmacology.

[153]  A. Janowsky,et al.  Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor. , 2003, European journal of pharmacology.

[154]  G. Miller,et al.  Altered ethanol-associated behaviors in vesicular monoamine transporter heterozygote knockout mice. , 2006, Alcohol.

[155]  T. Kosten,et al.  Atomoxetine Attenuates Dextroamphetamine Effects in Humans , 2009, The American journal of drug and alcohol abuse.

[156]  D. Gutman,et al.  Serotonin and norepinephrine transporter binding profile of SSRIs. , 2006, Essential psychopharmacology.

[157]  F. Vollenweider,et al.  Acute Psychological Effects of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”) are Attenuated by the Serotonin Uptake Inhibitor Citalopram , 1999, Neuropsychopharmacology.

[158]  G. Hanson,et al.  Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants. , 2001, The Journal of pharmacology and experimental therapeutics.

[159]  Pharmacotherapy with atomoxetine for US children and adolescents. , 2007, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

[160]  S. Karama,et al.  Dopamine Transporter 3′-UTR VNTR Genotype and ADHD: a Pharmaco-Behavioural Genetic Study with Methylphenidate , 2007, Neuropsychopharmacology.

[161]  D. Murphy,et al.  Cocaine reward models: conditioned place preference can be established in dopamine- and in serotonin-transporter knockout mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[162]  D. Eisenberg,et al.  A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter , 1992, Cell.

[163]  A. Batra,et al.  Association of the dopamine transporter gene with alcoholism. , 2005, Alcohol and alcoholism.

[164]  M. Geyer,et al.  Valproate attenuates hyperactive and perseverative behaviors in mutant mice with a dysregulated dopamine system , 2003, Biological Psychiatry.

[165]  M. Quick,et al.  Calcium/calmodulin-dependent kinase II regulates the interaction between the serotonin transporter and syntaxin 1A , 2008, Neuropharmacology.

[166]  A. Janowsky,et al.  The synthesis of bivalent 2beta-carbomethoxy-3beta-(3,4-dichlorophenyl)-8-heterobicyclo[3.2.1]octanes as probes for proximal binding sites on the dopamine and serotonin transporters. , 2008, Bioorganic & medicinal chemistry.

[167]  R. Blakely,et al.  A Regulated Interaction of Syntaxin 1A with the Antidepressant-Sensitive Norepinephrine Transporter Establishes Catecholamine Clearance Capacity , 2003, The Journal of Neuroscience.

[168]  Michael E Talkowski,et al.  A network of dopaminergic gene variations implicated as risk factors for schizophrenia. , 2008, Human molecular genetics.

[169]  R. Blakely,et al.  Cocaine and Antidepressant-Sensitive Biogenic Amine Transporters Exist in Regulated Complexes with Protein Phosphatase 2A , 2000, The Journal of Neuroscience.

[170]  J. Biederman,et al.  Effect of comorbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: a meta-analysis of controlled clinical trial data , 2006, Psychopharmacology.

[171]  F E Bloom,et al.  Central catecholamine neuron systems: anatomy and physiology of the norepinephrine and epinephrine systems. , 1979, Annual review of neuroscience.

[172]  A. Dunn,et al.  The role of corticotropin-releasing factor and noradrenaline in stress-related responses, and the inter-relationships between the two systems. , 2008, European journal of pharmacology.

[173]  E. Pothos,et al.  Vesicular Transport Regulates Monoamine Storage and Release but Is Not Essential for Amphetamine Action , 1997, Neuron.

[174]  P. Delgado.  How antidepressants help depression: mechanisms of action and clinical response. , 2004, The Journal of clinical psychiatry.

[175]  R. Gainetdinov,et al.  Increased Methamphetamine Neurotoxicity in Heterozygous Vesicular Monoamine Transporter 2 Knock-Out Mice , 1999, The Journal of Neuroscience.

[176]  J. Gelernter,et al.  Genetic Association between Dopamine Transporter Protein Alleles and Cocaine-Induced Paranoia , 1994, Neuropsychopharmacology.

[177]  J. Kelly,et al.  Activity and onset of action of reboxetine and effect of combination with sertraline in an animal model of depression. , 1999, European journal of pharmacology.

[178]  K. Lesch,et al.  Association and linkage of allelic variants of the dopamine transporter gene in ADHD , 2007, Molecular Psychiatry.

[179]  S. Hall,et al.  Psychological intervention and antidepressant treatment in smoking cessation. , 2002, Archives of general psychiatry.

[180]  C. Tsigos,et al.  Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. , 2002, Journal of psychosomatic research.

[181]  Sunti Tuntrakool,et al.  Norepinephrine Transporter-Deficient Mice Exhibit Excessive Tachycardia and Elevated Blood Pressure With Wakefulness and Activity , 2004, Circulation.

[182]  J. Scheys,et al.  Cocaine induction of dopamine transporter trafficking to the plasma membrane. , 2002, Molecular pharmacology.

[183]  E. Cook,et al.  Association of maternal dopamine transporter genotype with negative parenting: evidence for gene x environment interaction with child disruptive behavior , 2010, Molecular Psychiatry.

[184]  E D Levin,et al.  Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. , 1999, Science.

[185]  Jie Yang,et al.  Atomoxetine increases histamine release and improves learning deficits in an animal model of attention-deficit hyperactivity disorder: the spontaneously hypertensive rat. , 2008, Basic & clinical pharmacology & toxicology.

[186]  K. Lesch,et al.  Association of Anxiety-Related Traits with a Polymorphism in the Serotonin Transporter Gene Regulatory Region , 1996, Science.

[187]  A. Schene,et al.  Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. , 2006, The Journal of clinical psychiatry.

[188]  K. Arima,et al.  Behavioral and Brain Functions Association Study of the Vesicular Monoamine Transporter 1 (vmat1) Gene with Schizophrenia in a Japanese Population , 2022 .

[189]  G. Miller,et al.  Reduced MPTP toxicity in noradrenaline transporter knockout mice , 2004, Journal of neurochemistry.

[190]  D. Sulzer,et al.  Methamphetamine-Induced Degeneration of Dopaminergic Neurons Involves Autophagy and Upregulation of Dopamine Synthesis , 2002, The Journal of Neuroscience.

[191]  M. Kuhar,et al.  Cocaine receptors on dopamine transporters are related to self-administration of cocaine. , 1987, Science.

[192]  E. Jassem,et al.  Influences of polymorphic variants of DRD2 and SLC6A3 genes, and their combinations on smoking in Polish population , 2009, BMC Medical Genetics.

[193]  Jeffry D Madura,et al.  Molecular dynamics of leucine and dopamine transporter proteins in a model cell membrane lipid bilayer , 2010, Proteins.

[194]  J. Feighner,et al.  A fixed-dose (300 mg) efficacy study of bupropion and placebo in depressed outpatients. , 1990, The Journal of clinical psychiatry.

[195]  T. Humby,et al.  Age‐related decline in striatal dopamine content and motor performance occurs in the absence of nigral cell loss in a genetic mouse model of Parkinson's disease , 2006, The European journal of neuroscience.

[196]  A. Janssens,et al.  Meta-analyses of genetic studies on major depressive disorder , 2008, Molecular Psychiatry.

[197]  J. Javitch,et al.  Amphetamine-induced loss of human dopamine transporter activity: an internalization-dependent and cocaine-sensitive mechanism. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[198]  D. Murphy,et al.  Molecular mechanisms of cocaine reward: Combined dopamine and serotonin transporter knockouts eliminate cocaine place preference , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[199]  H. Sitte,et al.  Oligomerization of the Human Serotonin Transporter and of the Rat GABA Transporter 1 Visualized by Fluorescence Resonance Energy Transfer Microscopy in Living Cells* , 2001, The Journal of Biological Chemistry.

[200]  I. Lucki,et al.  Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test , 2005, Neuroscience & Biobehavioral Reviews.

[201]  L. Davis,et al.  Serotonin dysfunction disorders : A behavioral neurochemistry perspective. Discussion , 1996 .

[202]  G. Hanson,et al.  Cocaine Alters Vesicular Dopamine Sequestration and Potassium-Stimulated Dopamine Release: The Role of D2 Receptor Activation , 2009, Journal of Pharmacology and Experimental Therapeutics.

[203]  R. Gainetdinov,et al.  Functional hyperdopaminergia in dopamine transporter knock-out mice , 1999, Biological Psychiatry.

[204]  Ekaterina Boudanova,et al.  Dopamine transporter endocytic determinants: Carboxy terminal residues critical for basal and PKC-stimulated internalization , 2008, Molecular and Cellular Neuroscience.

[205]  J. Seibyl,et al.  Prediction of dopamine transporter binding availability by genotype: a preliminary report. , 2000, The American journal of psychiatry.

[206]  F. Zhou,et al.  Serotonin transporters are located on the axons beyond the synaptic junctions: anatomical and functional evidence , 1998, Brain Research.

[207]  P. Książek,et al.  Norepinephrine Transporter Gene (NET) Polymorphism in Patients with Type 2 Diabetes , 2007, Kidney and Blood Pressure Research.

[208]  W. Berrettini,et al.  Association between Polymorphisms in the Vesicular Monoamine Transporter 1 Gene (VMAT1/SLC18A1) on Chromosome 8p and Schizophrenia , 2008, Neuropsychobiology.

[209]  B. Balleine,et al.  Instrumental learning in hyperdopaminergic mice , 2006, Neurobiology of Learning and Memory.

[210]  Stefan Johansson,et al.  Multicenter Analysis of the SLC6A3/DAT1 VNTR Haplotype in Persistent ADHD Suggests Differential Involvement of the Gene in Childhood and Persistent ADHD , 2010, Neuropsychopharmacology.

[211]  J. Stockman,et al.  Dopamine Transporter Genotype Conveys Familial Risk of Attention-Deficit/Hyperactivity Disorder Through Striatal Activation , 2009 .

[212]  A. Janowsky,et al.  Pharmacological Profile of the “Triple” Monoamine Neurotransmitter Uptake Inhibitor, DOV 102,677 , 2006, Cellular and Molecular Neurobiology.

[213]  John P A Ioannidis,et al.  Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database , 2008, Nature Genetics.

[214]  S. Mandiyan,et al.  Cloning of the human brain GABA transporter , 1990, FEBS letters.

[215]  A. Grace,et al.  Chronic Stress Increases the Plasmalemmal Distribution of the Norepinephrine Transporter and the Coexpression of Tyrosine Hydroxylase in Norepinephrine Axons in the Prefrontal Cortex , 2006, The Journal of Neuroscience.

[216]  R. Gainetdinov,et al.  Potentiated Opioid Analgesia in Norepinephrine Transporter Knock-Out Mice , 2000, The Journal of Neuroscience.

[217]  R. Gainetdinov,et al.  Plasma membrane monoamine transporters: structure, regulation and function , 2003, Nature Reviews Neuroscience.

[218]  S. Iversen,et al.  Dopamine: 50 years in perspective , 2007, Trends in Neurosciences.

[219]  A. Sidhu,et al.  Modulation of the trafficking of the human serotonin transporter by human alpha‐synuclein , 2006, The European journal of neuroscience.

[220]  R. Spealman,et al.  Noradrenergic Mechanisms in Cocaine-Induced Reinstatement of Drug Seeking in Squirrel Monkeys , 2007, Journal of Pharmacology and Experimental Therapeutics.

[221]  M. Reith,et al.  Mutation of Trp84 and Asp313 of the dopamine transporter reveals similar mode of binding interaction for GBR12909 and benztropine as opposed to cocaine , 2004, Journal of neurochemistry.

[222]  B. Neale,et al.  Genome‐wide association study of response to methylphenidate in 187 children with attention‐deficit/hyperactivity disorder , 2008, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[223]  R. Blakely,et al.  Orthostatic intolerance and tachycardia associated with norepinephrine-transporter deficiency. , 2000, The New England journal of medicine.

[224]  Fang Liu,et al.  Dopamine transporter cell surface localization facilitated by a direct interaction with the dopamine D2 receptor , 2007, The EMBO journal.

[225]  H. Müller,et al.  Subcellular Redistribution of the Serotonin Transporter by Secretory Carrier Membrane Protein 2* , 2006, Journal of Biological Chemistry.

[226]  Paul Gissen,et al.  Homozygous loss-of-function mutations in the gene encoding the dopamine transporter are associated with infantile parkinsonism-dystonia. , 2009, The Journal of clinical investigation.

[227]  J. Homberg,et al.  Serotonin transporter dosage modulates long-term decision-making in rat and human , 2008, Neuropharmacology.

[228]  J. W. Aldridge,et al.  Sequential super-stereotypy of an instinctive fixed action pattern in hyper-dopaminergic mutant mice: a model of obsessive compulsive disorder and Tourette's , 2005, BMC Biology.

[229]  V. Faundez,et al.  A Biochemical and Functional Protein Complex Involving Dopamine Synthesis and Transport into Synaptic Vesicles , 2009, The Journal of Biological Chemistry.

[230]  A. Graybiel.  Habits, rituals, and the evaluative brain. , 2008, Annual review of neuroscience.

[231]  J. Canales,et al.  The high affinity dopamine uptake inhibitor, JHW 007, blocks cocaine-induced reward, locomotor stimulation and sensitization , 2010, European Neuropsychopharmacology.

[232]  K. Wimalasena.  Vesicular monoamine transporters: Structure‐function, pharmacology, and medicinal chemistry , 2011, Medicinal research reviews.

[233]  H. Niznik,et al.  Direct binding and functional coupling of α‐synuclein to the dopamine transporters accelerate dopamine‐induced apoptosis , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[234]  T. Arinami,et al.  Identification of a novel polymorphism of the human dopamine transporter (DAT1) gene and the significant association with alcoholism , 1999, Molecular Psychiatry.

[235]  J. Boulenger,et al.  Association between violent suicidal behavior and the low activity allele of the serotonin transporter gene , 2001, Molecular Psychiatry.

[236]  Francis J McMahon,et al.  Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. , 2007, Archives of general psychiatry.

[237]  L. Polito,et al.  Serotonin Transporter Gene Polymorphic Element 5-HTTLPR Increases the Risk of Sporadic Parkinson’s Disease in Italy , 2009, European Neurology.

[238]  J. Javitch,et al.  Syntaxin 1A Interaction with the Dopamine Transporter Promotes Amphetamine-Induced Dopamine Efflux , 2008, Molecular Pharmacology.

[239]  H. Möller,et al.  World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and Continuation Treatment of Major Depressive Disorder , 2002, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[240]  Randy D. Blakely,et al.  Sequence variation in the human dopamine transporter gene in children with attention deficit hyperactivity disorder , 2005, Neuropharmacology.

[241]  M. Keller,et al.  Are benzodiazepines still the medication of choice for patients with panic disorder with or without agoraphobia? , 2003, The American journal of psychiatry.

[242]  D. Murphy,et al.  A clomipramine dosage reduction study in the course of long-term treatment of obsessive-compulsive disorder patients. , 1990, Psychopharmacology bulletin.

[243]  Ming D. Li,et al.  Characterization of a functional polymorphism in the 3' UTR of SLC6A4 and its association with drinking intensity. , 2009, Alcoholism, clinical and experimental research.

[244]  J. Licinio,et al.  Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association with major depression and antidepressant response in Mexican-Americans , 2009, Molecular Psychiatry.

[245]  S. E. Stewart,et al.  Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorder. , 2003, The American journal of psychiatry.

[246]  B. Guptaroy,et al.  Regulation of Amphetamine-stimulated Dopamine Efflux by Protein Kinase C β* , 2005, Journal of Biological Chemistry.

[247]  L. Howell,et al.  Monoamine transporters and psychostimulant addiction. , 2008, Biochemical pharmacology.

[248]  J. W. Aldridge,et al.  Hyperdopaminergic mutant mice have higher "wanting" but not "liking" for sweet rewards. , 2004, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[249]  S. Kulkarni,et al.  Current investigational drugs for major depression , 2009 .

[250]  R. Blakely,et al.  Structural determinants of species‐selective substrate recognition in human and Drosophila serotonin transporters revealed through computational docking studies , 2009, Proteins.

[251]  S. Rana,et al.  Serotonin Transporter Promoter Variant: Analysis in Indian IBS Patients and Control Population , 2009, Journal of clinical gastroenterology.

[252]  H. J. Olverman,et al.  Sex influences the effect of a lifelong increase in serotonin transporter function on cerebral metabolism , 2009, Journal of neuroscience research.

[253]  Zhengming Chen,et al.  Designing new treatments for depression and anxiety. , 2008, IDrugs : the investigational drugs journal.

[254]  D. Sulzer,et al.  Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[255]  M. Keller,et al.  Use of benzodiazepines and selective serotonin reuptake inhibitors in middle-aged and older adults with anxiety disorders: a longitudinal and prospective study. , 2008, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[256]  P. Willner.  Dopamine and Depression , 2002 .

[257]  M. Kuhar,et al.  The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[258]  A. Zwinderman,et al.  The association of the dopamine transporter gene and the dopamine receptor 2 gene with delirium, a meta‐analysis , 2010, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[259]  Christina N. Lessov-Schlaggar,et al.  Dopamine genes and nicotine dependence in treatment seeking and community smokers , 2009, Neuropsychopharmacology.

[260]  P. Joyce,et al.  Relationships Between Angry-Impulsive Personality Traits and Genetic Polymorphisms of the Dopamine Transporter , 2009, Biological Psychiatry.

[261]  H. Sitte,et al.  Amphetamines take two to tango: an oligomer-based counter-transport model of neurotransmitter transport explores the amphetamine action. , 2005, Molecular pharmacology.

[262]  J. Canales,et al.  A dopamine transport inhibitor with markedly low abuse liability suppresses cocaine self-administration in the rat , 2009, Psychopharmacology.

[263]  R. Shelton.  The dual-action hypothesis: does pharmacology matter? , 2004, The Journal of clinical psychiatry.

[264]  H. Niznik,et al.  Direct binding and functional coupling of α-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[265]  M. Loder,et al.  Nonclassical, distinct endocytic signals dictate constitutive and PKC-regulated neurotransmitter transporter internalization , 2005, Nature Neuroscience.

[266]  G. Miller,et al.  Nonmotor Symptoms of Parkinson's Disease Revealed in an Animal Model with Reduced Monoamine Storage Capacity , 2009, The Journal of Neuroscience.

[267]  H. Gu,et al.  Lack of Cocaine Self-Administration in Mice Expressing a Cocaine-Insensitive Dopamine Transporter , 2009, Journal of Pharmacology and Experimental Therapeutics.

[268]  R. Blakely,et al.  Transmembrane Domain 6 of the Human Serotonin Transporter Contributes to an Aqueously Accessible Binding Pocket for Serotonin and the Psychostimulant 3,4-Methylene Dioxymethamphetamine* , 2010, Journal of Biological Chemistry.

[269]  D. Murphy,et al.  Abnormal anxiety‐related behavior in serotonin transporter null mutant mice: the influence of genetic background , 2003, Genes, brain, and behavior.

[270]  M. Hersberger,et al.  Genetic Polymorphisms of the Serotonin Transporter, but Not the 2a Receptor or Nitric Oxide Synthetase, Are Associated with Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease , 2009, Respiration.

[271]  G. Uhl,et al.  Cloning and expression of a cocaine-sensitive dopamine transporter complementary DNA. , 1991, Science.

[272]  C. Nemeroff,et al.  The role of dopamine in the pathophysiology of depression. , 2007, Archives of general psychiatry.

[273]  J. Shih,et al.  Monoamine oxidase inactivation: from pathophysiology to therapeutics. , 2008, Advanced drug delivery reviews.

[274]  D. Blackwood,et al.  Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy , 2009, The Pharmacogenomics Journal.

[275]  J. Homberg,et al.  Serotonin transporter deficiency in rats improves inhibitory control but not behavioural flexibility , 2007, The European journal of neuroscience.

[276]  R. Blakely,et al.  Tyr-95 and Ile-172 in Transmembrane Segments 1 and 3 of Human Serotonin Transporters Interact to Establish High Affinity Recognition of Antidepressants* , 2006, Journal of Biological Chemistry.

[277]  M. Loder,et al.  The Dopamine Transporter Constitutively Internalizes and Recycles in a Protein Kinase C-regulated Manner in Stably Transfected PC12 Cell Lines* , 2003, Journal of Biological Chemistry.

[278]  H. Melikian.  Neurotransmitter transporter trafficking: endocytosis, recycling, and regulation. , 2004, Pharmacology & therapeutics.

[279]  R. Murray,et al.  A dopamine transporter gene functional variant associated with cocaine abuse in a Brazilian sample. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[280]  P. Emson,et al.  Reduced vesicular storage of dopamine exacerbates methamphetamine‐induced neurodegeneration and astrogliosis , 2008, Journal of neurochemistry.

[281]  Eric Gouaux,et al.  Crystal structure of a bacterial homologue of Na+/Cl--dependent neurotransmitter transporters , 2005, Nature.

[282]  Klaus-Peter Lesch,et al.  Mice Lacking the Serotonin Transporter Exhibit 5-HT1A Receptor-Mediated Abnormalities in Tests for Anxiety-like Behavior , 2003, Neuropsychopharmacology.

[283]  A. Newman,et al.  Discovery of drugs to treat cocaine dependence: behavioral and neurochemical effects of atypical dopamine transport inhibitors. , 2009, Advances in pharmacology.

[284]  Henry R. Kranzler,et al.  Genetic Association between Dopamine Transporter Protein Alleles and Cocaine-Induced Paranoia , 1995, Neuropsychopharmacology.

[285]  Fuat Balci,et al.  Motivational effects on interval timing in dopamine transporter (DAT) knockdown mice , 2010, Brain Research.

[286]  H. Lester,et al.  Cloning and expression of a rat brain GABA transporter. , 1990, Science.

[287]  M. Millan,et al.  Physical interaction between the serotonin transporter and neuronal nitric oxide synthase underlies reciprocal modulation of their activity , 2007, Proceedings of the National Academy of Sciences.

[288]  A. Cools,et al.  Acute tryptophan depletion dose dependently impairs object memory in serotonin transporter knockout rats , 2008, Psychopharmacology.

[289]  S. Amara,et al.  Neurotransmitter transporters: recent progress. , 1993, Annual review of neuroscience.

[290]  Robert L Stephens,et al.  Abolished cocaine reward in mice with a cocaine-insensitive dopamine transporter. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[291]  C. Pennartz,et al.  The nucleus accumbens as a complex of functionally distinct neuronal ensembles: An integration of behavioural, electrophysiological and anatomical data , 1994, Progress in Neurobiology.

[292]  George R. Uhl,et al.  Dramatically Decreased Cocaine Self-Administration in Dopamine But Not Serotonin Transporter Knock-Out Mice , 2009, The Journal of Neuroscience.

[293]  Thomas G Schulze,et al.  Association between a serotonin transporter length polymorphism and primary insomnia. , 2010, Sleep.

[294]  L. Davis,et al.  Long-Term Pharmacotherapy for Post-Traumatic Stress Disorder , 2006, CNS drugs.

[295]  A. Sorkin,et al.  RNA Interference Screen Reveals an Essential Role of Nedd4–2 in Dopamine Transporter Ubiquitination and Endocytosis , 2006, The Journal of Neuroscience.

[296]  J. Stapleton,et al.  GENETIC STUDY: Association between dopamine transporter genotypes and smoking cessation: a meta‐analysis , 2007, Addiction biology.

[297]  M. Stein,et al.  Novel and functional norepinephrine transporter protein variants identified in attention-deficit hyperactivity disorder , 2009, Neuropharmacology.

[298]  D. Schaid,et al.  SLC6A4 variation and citalopram response , 2009, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[299]  G. Breen,et al.  Dopamine transporter polymorphisms are associated with short-term response to smoking cessation treatment , 2007, Pharmacogenetics and genomics.

[300]  B. Madras,et al.  Human genetics and pharmacology of neurotransmitter transporters. , 2006, Handbook of experimental pharmacology.

[301]  T. Robbins,et al.  Similar Effects of the Selective Noradrenaline Reuptake Inhibitor Atomoxetine on Three Distinct Forms of Impulsivity in the Rat , 2008, Neuropsychopharmacology.

[302]  Fei Xu,et al.  Knockout of the Vesicular Monoamine Transporter 2 Gene Results in Neonatal Death and Supersensitivity to Cocaine and Amphetamine , 1997, Neuron.

[303]  R. Baldessarini,et al.  Tolerance in Antidepressant Treatment , 2002, Psychotherapy and Psychosomatics.

[304]  R. Staud.  Pharmacological Treatment of Fibromyalgia Syndrome , 2012, Drugs.

[305]  Klaus-Peter Lesch,et al.  3,4-Methylenedioxymethamphetamine Self-Administration is Abolished in Serotonin Transporter Knockout Mice , 2007, Biological Psychiatry.

[306]  R. Wightman,et al.  Increased amphetamine-induced hyperactivity and reward in mice overexpressing the dopamine transporter , 2008, Proceedings of the National Academy of Sciences.

[307]  J. Kelly,et al.  Reboxetine attenuates forced swim test-induced behavioural and neurochemical alterations in the rat. , 1999 .

[308]  R. Blakely,et al.  Proteomic analysis of human norepinephrine transporter complexes reveals associations with protein phosphatase 2A anchoring subunit and 14-3-3 proteins. , 2005, Biochemical and biophysical research communications.

[309]  I. Lucki,et al.  Noradrenergic lesions differentially alter the antidepressant-like effects of reboxetine in a modified forced swim test. , 2002, European journal of pharmacology.

[310]  R. Blakely,et al.  Phosphorylation and sequestration of serotonin transporters differentially modulated by psychostimulants. , 1999, Science.

[311]  D. Klein.  Delineation of two drug-responsive anxiety syndromes , 1964, Psychopharmacologia.

[312]  D. Grandy,et al.  Vesicular Dopamine Release Elicits an Inhibitory Postsynaptic Current in Midbrain Dopamine Neurons , 2004, Neuron.

[313]  H. Sitte,et al.  Physical and Functional Interaction between the Dopamine Transporter and the Synaptic Vesicle Protein Synaptogyrin-3 , 2009, The Journal of Neuroscience.

[314]  B. Cagniard,et al.  Cocaine reward and locomotion stimulation in mice with reduced dopamine transporter expression , 2007, BMC Neuroscience.

[315]  M. Rice,et al.  Novel Ca2+ Dependence and Time Course of Somatodendritic Dopamine Release: Substantia Nigra versus Striatum , 2001, The Journal of Neuroscience.

[316]  E. Peselow,et al.  Discontinuation of maintenance selective serotonin reuptake inhibitor monotherapy after 5 years of stable response: a naturalistic study. , 2008, The Journal of clinical psychiatry.

[317]  G. Uhl,et al.  The interaction of methylphenidate and benztropine with the dopamine transporter is different than other substrates and ligands. , 2005, Biochemical pharmacology.

[318]  I. Sora,et al.  Dopaminergic Role in Stimulant-Induced Wakefulness , 2001, The Journal of Neuroscience.

[319]  H. Gu,et al.  Dopamine transporter inhibition is required for cocaine-induced stereotypy , 2008, Neuroreport.

[320]  T. Tencomnao,et al.  Association of C/T polymorphism in intron 14 of the dopamine transporter gene (rs40184) with major depression in a northeastern Thai population. , 2010, Genetics and molecular research : GMR.

[321]  G. Papakostas.  Tolerability of modern antidepressants. , 2008, The Journal of clinical psychiatry.

[322]  E. Galperin,et al.  Oligomerization of Dopamine Transporters Visualized in Living Cells by Fluorescence Resonance Energy Transfer Microscopy* , 2003, Journal of Biological Chemistry.

[323]  L. Knorring,et al.  Citalopram in patients with fibromyalgia— a randomized, double‐blind, placebo‐controlled study , 2000, European journal of pain.

[324]  R. Lewis,et al.  χ-Conotoxin and Tricyclic Antidepressant Interactions at the Norepinephrine Transporter Define a New Transporter Model* , 2007, Journal of Biological Chemistry.

[325]  S. Amara,et al.  Dynamic regulation of the dopamine transporter. , 2003, European journal of pharmacology.

[326]  Fei Xu,et al.  Mice lacking the norepinephrine transporter are supersensitive to psychostimulants , 2000, Nature Neuroscience.

[327]  H Ujike,et al.  VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[328]  Yiyun Huang,et al.  Serotonin Transporter Availability in Patients with Schizophrenia: A Positron Emission Tomography Imaging Study with [11C]DASB , 2005, Biological Psychiatry.

[329]  R. Todd,et al.  Prenatal Smoking Exposure and Dopaminergic Genotypes Interact to Cause a Severe ADHD Subtype , 2007, Biological Psychiatry.

[330]  G. Rudnick,et al.  The Third Transmembrane Domain of the Serotonin Transporter Contains Residues Associated with Substrate and Cocaine Binding* , 1997, The Journal of Biological Chemistry.

[331]  C. Evren,et al.  An open clinical trial of venlafaxine in the treatment of pain, depressive and anxiety symptoms in fibromyalgia , 2006 .

[332]  D. Stein,et al.  Sustained response versus relapse: the pharmacotherapeutic goal for obsessive–compulsive disorder , 2007, International clinical psychopharmacology.

[333]  Heinz Bönisch,et al.  Knockout of the norepinephrine transporter and pharmacologically diverse antidepressants prevent behavioral and brain neurotrophin alterations in two chronic stress models of depression , 2009, Journal of neurochemistry.

[334]  S. Greenland,et al.  Multivariate Meta-Analysis of Controlled Drug Studies for Obsessive-Compulsive Disorder , 2002, Journal of clinical psychopharmacology.

[335]  I. Sora,et al.  Sex-Dependent Modulation of Ethanol Consumption in Vesicular Monoamine Transporter 2 (VMAT2) and Dopamine Transporter (DAT) Knockout Mice , 2003, Neuropsychopharmacology.

[336]  Aribert Rothenberger,et al.  Genome‐wide association scan of quantitative traits for attention deficit hyperactivity disorder identifies novel associations and confirms candidate gene associations , 2008, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[337]  Da-Neng Wang,et al.  LeuT-Desipramine Structure Reveals How Antidepressants Block Neurotransmitter Reuptake , 2007, Science.

[338]  Barry Honig,et al.  Identification of a chloride ion binding site in Na+/Cl−-dependent transporters , 2007, Proceedings of the National Academy of Sciences.

[339]  L. Daws.  Unfaithful neurotransmitter transporters: focus on serotonin uptake and implications for antidepressant efficacy. , 2009, Pharmacology & therapeutics.

[340]  A. Sorkin,et al.  Trafficking of dopamine transporters in psychostimulant actions. , 2009, Seminars in cell & developmental biology.

[341]  L. Kozlowski,et al.  Smoking status and the human dopamine transporter variable number of tandem repeats (VNTR) polymorphism: failure to replicate and finding that never-smokers may be different. , 2002, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[342]  A. Sorkin,et al.  Constitutive and Protein Kinase C‐Induced Internalization of the Dopamine Transporter is Mediated by a Clathrin‐Dependent Mechanism , 2005, Traffic.

[343]  G. Uhl,et al.  Cocaine reward and MPTP toxicity: alteration by regional variant dopamine transporter overexpression. , 1999, Brain research. Molecular brain research.

[344]  R. Moore,et al.  Serotonin neurons of the midbrain raphe: Ascending projections , 1978, The Journal of comparative neurology.

[345]  D. Murphy,et al.  Hypolocomotion, anxiety and serotonin syndrome‐like behavior contribute to the complex phenotype of serotonin transporter knockout mice , 2007, Genes, brain, and behavior.

[346]  J. Sasse,et al.  A 40-basepair VNTR polymorphism in the dopamine transporter (DAT1) gene and the rapid response to antidepressant treatment , 2007, The Pharmacogenomics Journal.

[347]  J. Javitch,et al.  N-terminal Truncation of the Dopamine Transporter Abolishes Phorbol Ester- and Substance P Receptor-stimulated Phosphorylation without Impairing Transporter Internalization* , 2003, The Journal of Biological Chemistry.

[348]  G. Hanson,et al.  New insights into the mechanism of action of amphetamines. , 2007, Annual review of pharmacology and toxicology.

[349]  M. Humbert,et al.  Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. , 2001, The Journal of clinical investigation.

[350]  K. Murnane,et al.  The behavioral pharmacology of hallucinogens. , 2008, Biochemical pharmacology.

[351]  Jonathan A. Javitch,et al.  Mechanism of chloride interaction with neurotransmitter:sodium symporters , 2007, Nature.

[352]  J. Caballero,et al.  Atomoxetine hydrochloride for the treatment of attention-deficit/hyperactivity disorder. , 2003, Clinical therapeutics.